A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes

Guillermo Garcia-Manero, Stefan Faderl, Francis Giles, Deborah Thomas, Jorge Cortes, Susan O'Brien, Jan Davis, Hagop M. Kantarjian, Elihu Estey

Research output: Contribution to journalArticle

Abstract

Background and Objectives. Early studies have suggested that increasing doses of anthracycline improve outcome in younger patients with acute myelogenous leukemia (AML), but dose escalation has been precluded by the acute and chronic toxicities of these agents. Amifostine is a cytoprotective compound that has been shown to protect against the acute cytotoxicities of anthracyclines in animal models. We report the results of a phase I study of dose escalation of idarubicin with amifostine and high-dose ara-C in patients with relapsed or refractory AML or myelodysplastic syndrome (MDS). Design and Methods. The continuous reassessment method was used to predict the probability of toxicity. Results. Five patients were treated at an idarubicin dose of 18 mg/m2/day x 3, three of whom developed grade 3 diarrhea or mucositis. Subsequently, three additional patients were treated at a dose of 15 mg/m2 x 3 days, all of whom experienced grade 3 diarrhea or mucositis. One patient achieved complete remission (CR rate 12.5%, 95% Cl 0-0.52%). Interpretation and Conclusions. The addition of amifostine does not allow dose escalation of idarubicin when combined with high-dose ara-C.

Original languageEnglish (US)
Pages (from-to)804-807
Number of pages4
JournalHaematologica
Volume87
Issue number8
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Idarubicin
Amifostine
Myelodysplastic Syndromes
Cytarabine
Acute Myeloid Leukemia
Mucositis
Anthracyclines
Diarrhea
Animal Models

Keywords

  • Acute myelogenous leukemia
  • Amifostine
  • Cytarabine
  • Idarubicin
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology

Cite this

A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. / Garcia-Manero, Guillermo; Faderl, Stefan; Giles, Francis; Thomas, Deborah; Cortes, Jorge; O'Brien, Susan; Davis, Jan; Kantarjian, Hagop M.; Estey, Elihu.

In: Haematologica, Vol. 87, No. 8, 01.01.2002, p. 804-807.

Research output: Contribution to journalArticle

Garcia-Manero, G, Faderl, S, Giles, F, Thomas, D, Cortes, J, O'Brien, S, Davis, J, Kantarjian, HM & Estey, E 2002, 'A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes', Haematologica, vol. 87, no. 8, pp. 804-807.
Garcia-Manero, Guillermo ; Faderl, Stefan ; Giles, Francis ; Thomas, Deborah ; Cortes, Jorge ; O'Brien, Susan ; Davis, Jan ; Kantarjian, Hagop M. ; Estey, Elihu. / A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. In: Haematologica. 2002 ; Vol. 87, No. 8. pp. 804-807.
@article{a60bc04e5c7547719d185806dc9ecf5d,
title = "A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes",
abstract = "Background and Objectives. Early studies have suggested that increasing doses of anthracycline improve outcome in younger patients with acute myelogenous leukemia (AML), but dose escalation has been precluded by the acute and chronic toxicities of these agents. Amifostine is a cytoprotective compound that has been shown to protect against the acute cytotoxicities of anthracyclines in animal models. We report the results of a phase I study of dose escalation of idarubicin with amifostine and high-dose ara-C in patients with relapsed or refractory AML or myelodysplastic syndrome (MDS). Design and Methods. The continuous reassessment method was used to predict the probability of toxicity. Results. Five patients were treated at an idarubicin dose of 18 mg/m2/day x 3, three of whom developed grade 3 diarrhea or mucositis. Subsequently, three additional patients were treated at a dose of 15 mg/m2 x 3 days, all of whom experienced grade 3 diarrhea or mucositis. One patient achieved complete remission (CR rate 12.5{\%}, 95{\%} Cl 0-0.52{\%}). Interpretation and Conclusions. The addition of amifostine does not allow dose escalation of idarubicin when combined with high-dose ara-C.",
keywords = "Acute myelogenous leukemia, Amifostine, Cytarabine, Idarubicin, Myelodysplastic syndrome",
author = "Guillermo Garcia-Manero and Stefan Faderl and Francis Giles and Deborah Thomas and Jorge Cortes and Susan O'Brien and Jan Davis and Kantarjian, {Hagop M.} and Elihu Estey",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "87",
pages = "804--807",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "8",

}

TY - JOUR

T1 - A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes

AU - Garcia-Manero, Guillermo

AU - Faderl, Stefan

AU - Giles, Francis

AU - Thomas, Deborah

AU - Cortes, Jorge

AU - O'Brien, Susan

AU - Davis, Jan

AU - Kantarjian, Hagop M.

AU - Estey, Elihu

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Background and Objectives. Early studies have suggested that increasing doses of anthracycline improve outcome in younger patients with acute myelogenous leukemia (AML), but dose escalation has been precluded by the acute and chronic toxicities of these agents. Amifostine is a cytoprotective compound that has been shown to protect against the acute cytotoxicities of anthracyclines in animal models. We report the results of a phase I study of dose escalation of idarubicin with amifostine and high-dose ara-C in patients with relapsed or refractory AML or myelodysplastic syndrome (MDS). Design and Methods. The continuous reassessment method was used to predict the probability of toxicity. Results. Five patients were treated at an idarubicin dose of 18 mg/m2/day x 3, three of whom developed grade 3 diarrhea or mucositis. Subsequently, three additional patients were treated at a dose of 15 mg/m2 x 3 days, all of whom experienced grade 3 diarrhea or mucositis. One patient achieved complete remission (CR rate 12.5%, 95% Cl 0-0.52%). Interpretation and Conclusions. The addition of amifostine does not allow dose escalation of idarubicin when combined with high-dose ara-C.

AB - Background and Objectives. Early studies have suggested that increasing doses of anthracycline improve outcome in younger patients with acute myelogenous leukemia (AML), but dose escalation has been precluded by the acute and chronic toxicities of these agents. Amifostine is a cytoprotective compound that has been shown to protect against the acute cytotoxicities of anthracyclines in animal models. We report the results of a phase I study of dose escalation of idarubicin with amifostine and high-dose ara-C in patients with relapsed or refractory AML or myelodysplastic syndrome (MDS). Design and Methods. The continuous reassessment method was used to predict the probability of toxicity. Results. Five patients were treated at an idarubicin dose of 18 mg/m2/day x 3, three of whom developed grade 3 diarrhea or mucositis. Subsequently, three additional patients were treated at a dose of 15 mg/m2 x 3 days, all of whom experienced grade 3 diarrhea or mucositis. One patient achieved complete remission (CR rate 12.5%, 95% Cl 0-0.52%). Interpretation and Conclusions. The addition of amifostine does not allow dose escalation of idarubicin when combined with high-dose ara-C.

KW - Acute myelogenous leukemia

KW - Amifostine

KW - Cytarabine

KW - Idarubicin

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=0035986757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035986757&partnerID=8YFLogxK

M3 - Article

C2 - 12161355

AN - SCOPUS:0035986757

VL - 87

SP - 804

EP - 807

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -